This study will determine the effectiveness of a compound called ACH-0144471 at improving the clinical symptoms of C3G of IC-MPGN. Patients will participate for 1 year. ACH-0144471 is an oral tablet that study participants will take daily. Additional study visits and diagnostic tests may be required, including biopsies and labwork.
How To Contact a Study Center:
- Visit KidneyHealthGateway.com to see if you might be eligible and to contact a study site near you